Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Market Update 19 March

Jessica Amir
March 19, 2020

Morning Bell 18 March

Jessica Amir
March 18, 2020

Morning Bell 17 March

Jessica Amir
March 17, 2020

Market Update 16 March

Bell Direct
March 16, 2020

Weekly Wrap 13 March

Jessica Amir
March 13, 2020

Market Update 12 March

Paulina Peters
March 12, 2020

Morning Bell 11 March

Jessica Amir
March 11, 2020

ETF mini-series 3/3: Top ETF picks

Jessica Amir
March 10, 2020

Morning Bell 10 March

Jessica Amir
March 10, 2020